A persistent puzzle in cancer biology is how mutations, which neither alter canonical growth signaling pathways nor directly interfere with drug mechanism, can still recur and persist in tumors. One notable example is the loss-of-function mutation of the DNA demethylase Tet2 in acute myeloid leukemias (AMLs) that frequently persists from diagnosis through remission and relapse (Rothenberg-Thurley et al., 2018; Corces-Zimmerman et al., 2014; Nibourel et al., 2010) , but whose fitness advantage in the setting of anti-leukemic chemotherapy is unclear. Here we use paired isogenic human AML cell lines to show that Tet2 loss-of-function alters the dynamics of transitions between differentiated and stem-like states. Mathematical modeling and experimental validation reveal that these altered cell-state dynamics can benefit the cell population by slowing population decay during drug treatment and lowering the number of survivor cells needed to re-establish the initial population. These studies shed light on the functional and phenotypic effects of a Tet2 loss-of-function in AML, illustrate how a single gene mutation can alter a cells' phenotypic plasticity, and open up new avenues in the development of strategies to combat AML relapse.
Introduction
A major challenge in cancer biology is to understand the function of recurrent mutations in the emergence of tumors or response to drug therapy. Some mutations clearly benefit cancer populations either by 1) altering regulation of growth signaling or programmed cell death (e.g. mutations in p53 or TGFβ signaling, Sanchez-Vega, et al., 2018) or by 2) directly interfering with drug effect (e.g. acquired EGFR T790M resistance mutations in response to EGFR tyrosine kinase inhibitor therapy, Ma, Wei and Song, 2011). However, for many observed mutations it is unclear how they affect either proliferation or drug resistance.
One example are mutations in the DNA demethylase Tet2, found in ~15-20% of de novo AML patients (Nibourel et ). However, due to its ability to alter DNA methylation genome-wide, the mechanisms by which Tet2 mutation confers a benefit to AML cancer cell populations remain unclear. Here we investigate this puzzle using an integrated approach of mathematical modeling and experimentation in paired WT and Tet2-mutant isogenic human AML cell lines. We discover that Tet2 mutation alters the dynamics of transitions between distinct stem-like and differentiated cell states, which enhances population fitness in chemotherapy and lowers the number of cells needed to establish a cell population.
Results

Tet2 loss-of-function mutation renders AML cell populations more stem-cell like
To investigate the consequences of Tet2 mutation, we chose to compare two pairs of isogenic human myeloblast cell lines, each expressing wildtype or mutant Tet2 ( Figure 1A ). The AML cell lines KG1 and Thp1 (Kunimoto et al., 2018) were selected as they express wildtype Tet2 (Tet2 WT ) but do not express mutant FLT3, which is known to have synergistic epigenetic effects (Shish et al., 2015) . In human AMLs, Tet2 is often mutated in AML with truncating mutations or missense mutations in its catalytic domain (Hirsch et al., 2018) , resulting in Tet2 loss-of-function (Smith et al., 2010) . Therefore, isogenic cell lines were created by knocking out Tet2 in the chosen cell lines (Tet2 KO To gain an unbiased overview of the molecular changes induced by Tet2 KO , we examined the transcriptomic and epigenomic profiles of Tet2 WT and KO cell populations. RNAseq analysis identified ~300 gene transcripts that are similarly differentially expressed in both Tet2 KO cell lines (fold-change>2, Supplemental Figure 2B ). Notably, reduced expression of myeloid differentiation markers (ITGAM, CORO1A, Wald test, BH adjusted p-values 9.99e-9 and 7.73e-2, Figure 1C , Supplemental Figure 2C ) and increased expression of markers associated with leukemic progenitor cells (CD38 -, HLA-DRA -, TAL1, Wald test, BH adjusted p-values 3.83e-26, 1.74e-16, and 3.90e-7, Figure 1C , Supplemental Figure 2C ) (Nishioka et al., 2013) were observed. These data are consistent with analysis of TCGA LAML and OHSU datasets, which showed that Tet2 expression is strongly correlated with genes expressed in the granulocytic lineage (Fisher's exact test, adjusted p-values 8e-25 and 3.7e-19, Supplemental Tables 1-2, Methods) .
Differentially expressed genes in Tet2 KO cells were found to be highly enriched for targets of Runx1, a hematopoietic regulator known to promote stemness and myeloid fate decisions (Fisher's exact test, p-value 7.76e-6, Supplemental Figure 2D , Supplemental Tables 3-4 ) (Kuleshov et al., 2016; Ran et al., 2013) . Consistently, analysis of differentially methylated regions showed the proximal promoter of Runx1 to be significantly affected in Tet2 KO (Wald test, minimum adjusted p-value 1.22e-27, Supplemental Figure 2E ), with a concomitant increase in the expression the Runx1a isoform (Supplemental Figure 2F ). Methylcellulose colony forming unit assays of Tet2 KO cells also show increased numbers of colonies associated with oligopotent progenitor cells compared to Tet2 WT controls (CFUGEMMs, Figure 1D , Supplemental Figure 4A ).
Overall, these data suggested that Tet2 KO populations acquire more stem-like signatures, which was further validated by comparing their DNA methylation profiles to those of normal hematopoietic progenitors and leukemic stem cells (LSCs, Supplemental Figure 4B ,C) (Horvath, 2013; Jung et al., 2015) .
The Tet2 KO -mediated acquisition of stem-like signatures was much more pronounced in KG1 than Thp1 in terms of expression profile and potential to form diverse myeloid lineages in colony-forming assays (Supplemental Figure 4 ). This is presumably because the monocyte-like cells, Thp1, are already more differentiated than the myeloblast-like cells, KG1, regardless of Tet2 mutational status. We therefore chose to focus on KG1 cells for the remainder of this work.
Tet2 mutation changes dynamics of cell-state switching
To test whether this change in stem-like molecular signatures is caused by an increase in the fraction of cells with CD34 hi CD38 lo surface marker expression (a classic LSC-like profile (Nishioka et al., 2013) ) in Tet2 KO compared to Tet2 WT cells, we quantified CD34 and CD38 signals in the population using flow cytometry. Quantification of KG1 CD34/CD38 expression revealed that the fraction of CD34 hi CD38 lo cells was indeed increased in Tet2 KO cell populations ( Figure   2A ).
How does Tet2 KO alter the ratio between stem-like and differentiated cells? One possibility is that Tet2 KO simply reduces the rate of differentiation. To test this, subpopulations of stem-like ( , CD34 hi CD38 lo ) and differentiated ( , CD34 hi CD38 hi ) cells were sorted in both Tet2 WT and Tet2 KO populations, and the ratio of and cells was monitored over time ( Figure 2B , Supplemental Figure 5A ). Indeed, sorted stem-like cell populations repopulated the differentiated state more slowly in Tet2 KO ( Figure 2C , Supplemental Figure 5B) . Surprisingly, in Tet2 KO , the sorted differentiated cell populations repopulated the stem-cell like state more rapidly than Tet2 WT populations ( Figure 2D , Supplemental Figure 5B ). These data suggest that Tet2 KO facilitates the reversible switching from differentiated to stem-like states in AML cells and provides intuition for why Tet2 KO has a larger fraction of stem-like cells in the population.
Mathematical modeling illustrates consequences of altered cell-state dynamics for survival of cell population
What are the functional consequences of having such altered cell-state dynamics, and in particular a higher fraction of stem-like cells? To address this question, we developed a general mathematical model with three cell states (Figure 3 , second panel): a stem-cell-like state , a differentiated state , and an irreversible cell death state (to account for the impact of drug treatment). This model is fully characterized by a linear, homogeneous system of ordinary differential equations (ODEs) with 6 parameters with values ≥ 0 (Methods). Parameters are denoted by: ' and ( the death rates of the and states, respectively; ' and ( , the rates at which the and states proliferate; and '( and (' the transition rates from to and to , respectively.
Using this model, we asked under which circumstances the observed altered cell-state dynamics -specifically an increased switch rate towards a stem-like state -would benefit a cell population. First, we focused on the impact of such altered cell-state dynamics during drug treatment (i.e. high death rates). In this case, the time to population collapse is dominated by the largest negative eigenvalue; the less negative the eigenvalue, the slower the population collapse.
By computing the eigenvalues for the ODE, it can be seen that either increasing (' and/or decreasing '( slows population decay and "benefits" a drug-treated cancer population as long as ( Figure 3 , first panel; Methods):
This inequality simply compares net production rates (proliferation rate minus death rate) and requires it to be higher at than . In fact, as long as Inequality 1 is true, increasing (' , or decreasing '( will eventually slow population decay (arrows in phase plane diagram below; see Methods for details). Thus, as long as the net production rate of the stem-like state L exceeds that of the differentiated state H, altered cell state dynamics (i.e. towards a higher fraction of stemlike cells) will always benefit the cell population. This finding is in line with recent studies Importantly, the same inequality also captures other cases in which switching to a stemcell-like state is either beneficial or detrimental ( Figure 3 , third and fourth panels). If cells rarely die, such as in a non-drug-treated condition ( ' ≈ 0, ( ≈ 0) (Case 1), inequality 1 simplifies to propensity of differentiated cells to divide. In this case, we expect cells carrying mutations that increase (' to take over the population. Conversely, if the differentiated cell state were protected from the adverse effects of drug treatment ( ( ≈ 0) (Case 2), inequality 1 simplifies to ' − ' > ( Here, increasing (' is only beneficial for the cell population if the net production rate of is larger than the proliferation rate ( of the differentiated state , which is unlikely for high doses of drug ( ' ≫ 0). In this case, we expect cells carrying mutations that increase (' to be depleted from the population over time.
Overall, this general mathematical model shows that altered cell-state dynamicsspecifically an increased switch rate towards a stem-like state -can indeed benefit the cell population (both in presence or absence of drug treatment), as long as it falls within a parameter regime outlined by inequality 1 (i.e. net production rate of stem-like state exceeds that of the differentiated state).
Experimental validation of modeling predictions
Does the Tet2 mutation put the AML cancer population in this predicted advantageous parameter regime? Since the proliferation, death and switching rates cannot be disentangled directly from measurements, we estimated these rates by fitting our model to time course data of sorted Tet2 KO and WT populations in the presence of cytosine arabinoside (AraC, a common firstline chemotherapy drug for AML) (see Methods, Figure 4B ). These estimates confirmed that the proliferation rate during drug treatment of stem-like cells far exceeds that of differentiated cells, both for Tet2 KO and WT populations ( Figure 4A -B). Thus, both populations are in a regime where the net production of stem-like cells outstrips the net production of differentiated cells in drug treatment (as required by Inequality 1), and therefore switching to the stem-like state is more advantageous. The Tet2 KO populations have a higher → switching rate and a lower → switching rate; hence, the model predicts that the Tet2 KO population, as a whole, is more drug resistant. Indeed, drug treatment experiments confirmed that Tet2 KO populations are less sensitive to AraC and doxorubicin than Tet2 WT populations ( Figure 4C , Supplemental Figure 5C ).
Further analysis of the model suggested two additional predictions. First, the model suggested that a population with a higher fraction of differentiated cell states will show reduced population survival in drug treatment ( Figure 4D ). To test this conjecture, two effectors known to enrich AML cell populations for the differentiated state (without altering cell death, Supplemental Supplemental Table 5 ). Second, the model predicted that the increased ability of Tet2 KO to revert to a stem-like cell state (with its higher proliferation potential), will allow a Tet2 KO population to better regrow out of drug than a Tet2 WT population ( Figure 4G ). To test this prediction, we compared the number of colonies formed by Tet2 KO and Tet2 WT populations in methylcellulose assays, which assesses the ability of isolated cells to reform a colony ( Figure 4H ). As predicted, sorted stem-like cell populations showed increased cell colony numbers in both Tet2 KO and Tet2 WT populations.
Moreover, unsorted Tet2 KO populations formed approximately 2x more colonies than their Tet2 WT counterparts ( Figure 4I ), highlighting their increased potential for population renewal. Thus, our results suggest that Tet2 KO populations have a higher likelihood to regrow an AML population from few surviving cells in the setting of therapeutic perturbations.
Discussion
Taken together, our results reveal that mutation of the epigenetic modifier Tet2 in AML cell populations alters the transition dynamics between stem-like and differentiated cell states.
These altered cell-state dynamics confer several benefits to the population. First, Tet2 mutation enables differentiated cells to switch to a stem-like state whose increased drug sensitivity is compensated by a higher proliferation rate, thus increasing population survival. Second, Tet2 mutation increases the propensity to regrow an AML population after drug treatment from few surviving cells, due to the increased ability of Tet2 KO cells to revert back to a proliferative stemlike cell state ( Figure 4A ). These findings provide a rationale for why the detection of Tet2 mutants in patients in remission is strongly associated with a higher chance of relapse (Rothenberg- This work has important implications for AML mutations beyond Tet2: the mathematical model shows that as long as stem-like and differentiated cell states differ in their net cell production during drug treatment (i.e., Inequality 1 is fulfilled), any other mutation increasing the transition rate towards the stem-like state will be beneficial as well. Thus, we conjecture that mutations in other epigenetic modifiers might confer a fitness advantage to drug-treated AML populations through similar mechanisms. 
STAR Methods
Cell-state transition model
We modeled a cell system with states as a linear, homogenous system of ODEs. In matrix form this is written as = where is cell-state vector of length , and is a matrix representing cell-state transitions.
We do not assume the matrix is stochastic, which allows expansion or contraction of the total number of cells in the system-reflecting cell division or drug sensitivity-to occur. In our study, To find the regime where changing (asympototically) increases survival rate, we focus on the larger of the other two eigenvalues, namely . Taking the derivative of with respect to the state-switching parameters gives: . Primer sequences for human Runx1, Tet2 and GAPDH were as previously described 28 .
Methylation age and Stemness score
Quantile normalized values from the aforementioned ChAMP analysis were used as input to the DNA methylation age calculator in R as described in the tutorial (horvath.genetics.ucla.edu) (Horvath, 2013) . For visualization purposes, results for Tet2 WT and Tet2 KO cells were normalized to Tet2 WT .
For the "stem-like" epigenetic signatures, we used a publicly available dataset of DNA methylation profiles from normal hematopoietic progenitors and leukemic cells sorted by CD34/CD38 expression (Jung et al., 2015) . Linear discriminant analysis (LDA) was applied using the MASS package (version 7.3-51.4) in R to identify an optimal transform that increased separation of DNA methylation profiles across three key reference populations: normal HSCs, CD34 + CD38putative LSCs, and CD34leukemia cells. The rest of the public dataset, as well as methylation data from the paired Tet2 WT /Tet2 KO cell lines, was projected into the lower-dimensional LDA space. The final "stemness score" was simply the LD2 value of the query methylation profile in LD space. A constant was added to the final score for visualization purposes.
Flow cytometry
Cells were pelleted and washed with 250uL wash buffer (HBSS + 1% BSA, filtered with a 50mL
Steriflip unit (Millipore, Burlington, MA)) prior to a 30m incubation in Fc Receptor Blocker (Innovex Biosciences, Richmond, CA) on ice in the dark. Cells were then washed twice before resuspension in wash buffer containing conjugated antibodies for flow cytometry at their recommended concentrations (Becton Dickinson, Franklin Lakes, NJ), and incubation for 30m on ice in the dark. Cells were then washed three times prior to flow cytometry. Doublets were called based on gates drawn for FSC-A and FSC-W, and dead cells were counted based on gates drawn in FSC-A and SSC-A. Gates for fluorescent markers were selected based on the background fluorescence of unstained controls, such that <5% of nonspecific cells would be counted as positively stained. All flow cytometry or FACS was performed on the Aria IIu in the Center for Advanced Technologies at UC San Francisco.
MethoCult methylcellulose colony forming assay
Cells were counted with the TC20 automatic cell counter (Bio-Rad) with Trypan blue prior to plating in triplicate (as technical replicates) and incubation for 2 weeks at 37°C with 5% CO2.
Colonies were then enumerated using MethoCult H4034 Optimum (Stemcell Technologies, Vancouver, CAN) according to the manufacturer's instructions. Results shown are representative results from two independent experiments.
Cell viability assays
For sorted drug sensitivity assays, cells were sorted with gates as previously described, and treated with drug. After 72h, dead cells were counted based on gates in FSC-A and SSC-A.
For effector viability assays, cells were plated as technical replicates at 1e5 cells/mL with a WellMate (Thermo Fisher Scientific) and treated with drug or effector for 72h unless otherwise noted. Effectors were added with the Echo 525 (Labcyte, San Jose, CA). For readout, plates were allowed to cool to room temperature before combining well-mixed cells and cell media 1: 
